Yi Ting
Southern University of Science and Technology Hospital, Shenzhen, Guangdong, China.
PLoS One. 2025 Feb 6;20(2):e0318511. doi: 10.1371/journal.pone.0318511. eCollection 2025.
While drug therapy and allergen immunotherapy are useful for alleviating symptoms of seasonal allergic rhinitis (AR), existing therapeutic options remain limited. Cuproptosis is a novel form of programmed cell death, and its role in allergic rhinitis has not yet been explored. Researching the interaction between cuproptosis and allergic rhinitis will likely pave the way for future treatment of this disease.
A microarray dataset of AR patients and normal controls (GSE43523) were obtained from the Gene Expression Omnibus (GEO) database for differential gene analysis. Cuproptosis related genes were extracted from the differentially expressed genes (DEGs) to form the AR/cuprotosis-gene set and analyzed by the GO and KEGG databases. Intersection analysis further defined the AR signature genes (AR-sg). Consensus cluster analyses were used to define the AR/cuprotosis-genes into subsets. Finally, AR signature genes were used as targets for drug prediction and molecular docking to identify candidate drugs that may affect SAR.
Four AR signature genes (MRPS30, CLPX, MRPL13, and MRPL53) were selected by the MCC, EPC, BottleNeck, and Closeness algorithms. Correlation analysis of the AR signature genes and immune genes showed strong interactions; xCell analysis identified multiple immune cell types and supported these cells' importance in the AR pathogenesis. Finally, drug target analysis suggests that 1,5-isoquinolinediol and gefitinib have the potential to become future AR treatments.
Our study analyzed allergic rhinitis and cuproptosis related genes by the bioinformatics approach and predicted 1,5-isoquinolinediol and gefitinib as potentially useful drugs for treating AR patients in the future.
虽然药物治疗和变应原免疫疗法有助于缓解季节性变应性鼻炎（AR）的症状，但现有的治疗选择仍然有限。铜死亡是一种新型的程序性细胞死亡形式，其在变应性鼻炎中的作用尚未得到探索。研究铜死亡与变应性鼻炎之间的相互作用可能会为该疾病的未来治疗铺平道路。
从基因表达综合数据库（GEO）中获取AR患者和正常对照的微阵列数据集（GSE43523）进行差异基因分析。从差异表达基因（DEG）中提取铜死亡相关基因，形成AR/铜死亡基因集，并通过GO和KEGG数据库进行分析。交叉分析进一步确定了AR特征基因（AR-sg）。采用共识聚类分析将AR/铜死亡基因定义为子集。最后，将AR特征基因用作药物预测和分子对接的靶点，以识别可能影响季节性变应性鼻炎（SAR）的候选药物。
通过MCC、EPC、瓶颈和接近度算法选择了四个AR特征基因（MRPS30、CLPX、MRPL13和MRPL53）。AR特征基因与免疫基因的相关性分析显示出强烈的相互作用；xCell分析确定了多种免疫细胞类型，并支持这些细胞在AR发病机制中的重要性。最后，药物靶点分析表明1,5-异喹啉二醇和吉非替尼有可能成为未来AR的治疗药物。
我们的研究通过生物信息学方法分析了变应性鼻炎和铜死亡相关基因，并预测1,5-异喹啉二醇和吉非替尼是未来治疗AR患者的潜在有用药物。
